Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 Patients

摘要: Abstract Background The combination of paclitaxel and bevacizumab was EMA-approved as first-line therapy in metastatic breast cancer. Moreover, vitro studies showed a potential antiangiogenic synergistic effect bevacizumab. Methods Between November 2008 March 2010, this case series study included 15 patients with non squamous-cell lung carcinoma (NSCLC). Those were eligible received the same regimen used cancer weekly (80 mg/m 2 , days 1, 8 15) (10 mg/kg at 1 after least one prior line chemotherapy. Efficacy evaluated by CT-scan PET-FDG every two months. Circulating endothelial progenitor cells (CEP) circulating (CEC) levels explored subset patients. Results Median age 56 (36-75), female: 47%, never smokers: 27%, adenocarcinoma: 100%, PS 0-1: 87% 3: 13%. All treated platinum-based doublet or without 70% them erlotinib second-line. No major toxicity observed. Partial response (PR) rate 44% (31-63%) using RECIST criteria on CT-scan, 65% (29-88%) PET FDG. improved 33% cases. progression free survival 4.6 An increase CEC CEP observed NSCLC Conclusion In retrospective series, our results suggest efficacy signal pre-treated warrant further assessment randomized clinical trial.